Business Wire

GALDERMA

7.2.2024 07:01:36 CET | Business Wire | Press release

Share
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics

Galderma, the emerging pure-play dermatology category leader, is proud to present “NEXT by Galderma.” A ground-breaking report, NEXT takes a deep-dive into the global aesthetics trends set to shape 2024 and beyond. This project is the culmination of a year of comprehensive trend-forecasting research, conducted in collaboration with a network of renowned experts.

Aesthetics is increasingly becoming part of holistic beauty and well-being routines, which are, in turn, driving the category’s projected growth. By 2028, the aesthetics market is predicted to nearly double in value, reaching $25.9 billion.1

NEXT by Galderma offers a future-forward perspective on the aesthetics industry. The report identifies six key emerging trends, bolstered by three core macro movements that are supporting industry growth. These six key trends have the potential to shape the aesthetics landscape and become mainstream in the future. The report takes an in-depth look at these trends from a neutral standpoint, as well as at the societal and cultural aspects underpinning the evolution of the aesthetics industry.

Commissioned by Galderma and based on research from a leading trend-forecasting authority, the report is informed by extensive data and analysis. NEXT by Galderma was co-developed by a network of almost 40 of the world’s leading healthcare professionals and esteemed beauty and skincare influencers.

 

“In partnership with a renowned trend-forecasting agency, and in collaboration with revered healthcare professionals and influencers, we’ve identified six trends poised to shape the future of aesthetics. The trends that we see emerging now have the potential to become bigger and impact consumer decisions regarding their beauty and skincare choices. At Galderma, everything we do in the world of aesthetics is a manifestation of our belief in “Aesthetic Possibilities, Shaped Together.” It’s a new, more collaborative and future-facing approach that is at the core of NEXT by Galderma.”

 

GERRY MUHLE

HEAD OF GLOBAL PRODUCT STRATEGY

GALDERMA

 

NEXT by Galderma: The six trends that are anticipated to shape consumer demand in aesthetics

  1. Proactive Beauty: Addressing aging before it is apparent has become paramount. The rise of “prejuvenation” treatments, which focus on prevention rather than cure, reflects today’s zeitgeist. For aesthetics, this means an increased shift toward early intervention.
  2. Mindful Aesthetics: The ethos of mindful beauty has reached the aesthetics market. Consumers are increasingly embracing products with minimal environmental impact that align with their ethical values and provide natural-looking results. Additionally, there is demand for products that seamlessly integrate with the body, indicating a push-back against artifice.
  3. Fast Aesthetics: That trends in fashion and cosmetics come and go is nothing new. But the addition of aesthetics treatments into the mix is a more recent—and noteworthy—development. More and more people now want to use aesthetics to mimic the latest fast-moving trends.
  4. Beauty Fandom: There is a new and more extreme take on fandom at play in the aesthetics world today. This trend indulges in fascination with niche idolization—from cultural icons to digital filters, anime, and beyond—which is leading to a desire for metamorphosis.
  5. Expressionality: There is greater interplay between a sense of self and self-expression. We live in an era that encourages individuality in fashion, styling, hair, makeup and, now, aesthetic treatments. This trend celebrates the empowerment that comes from creating and enhancing one’s identity with aesthetics.
  6. Cancelling Age: Beauty today is for every age, at any age. We are cancelling expectations of what certain ages “should look like,” as consumers employ aesthetics to express their ageless attitude. This trend shows how the evolving desire to not be defined by our age is increasing demand to preserve and enhance beauty, rather than solely reverse aging.

The six trends are underpinned by three macro movements:

  1. Increasing accessibility: More convenient, more affordable, more inclusive. The exponential rise of minimally invasive treatments, as well as increased access to treatments via new clinic locations and treatment options, are factors that have reshaped the beauty industry. The desire for inclusivity has had a major impact on the world of aesthetics at large.
  2. Advancements in science and technology: The rise of aesthetic tech, new product innovations and improvements on existing products have expanded not only the variety of treatment options available, but also their appeal.
  3. Social community: Social media has heightened consumer awareness and understanding around aesthetic treatments. Aesthetic practitioners are using social media to garner sizeable followings, highlighting that the world of aesthetics has a far-reaching platform of increasing influence.

As Galderma continues to navigate what lies ahead, driven by “Aesthetic Possibilities, Shaped Together,” there remains a firm focus on advancing dermatology for every skin story. The skin we’re in shapes our lives. That’s why Galderma’s unparalleled portfolio—along with our commitment to staying at the forefront of emerging technologies, medical education, thought leadership and training—is essential to shaping the future of aesthetics.

To view the abridged version of the NEXT by Galderma report, click here.

About Galderma

Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we’re in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

  1. Markets and Markets (2022): Medical Aesthetics Market - Global Forecast to 2027. Hadapsar: Markets and Markets, pp. 1–257. Available at: https://www.marketsandmarkets.com/Market-Reports/medical-aesthetics-market-885.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206624555/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye